1 Market Overview 1.1 Neurofibromatosis Type 1 Introduction 1.2 Market Analysis by Type 1.2.1 Overview: Global Neurofibromatosis Type 1 Revenue by Type: 2015 VS 2019 VS 2025 1.2.2 10 mg 1.2.3 25 mg 1.3 Market Analysis by Application 1.3.1 Overview: Global Neurofibromatosis Type 1 Revenue by Application: 2015 VS 2019 VS 2025 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Overview of Global Neurofibromatosis Type 1 Market 1.4.1 Global Neurofibromatosis Type 1 Market Status and Outlook (2015-2025) 1.4.2 North America (United States, Canada and Mexico) 1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy) 1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 1.4.5 South America, Middle East & Africa 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 AstraZeneca 2.1.1 AstraZeneca Details 2.1.2 AstraZeneca Major Business 2.1.3 AstraZeneca SWOT Analysis 2.1.4 AstraZeneca Product and Services 2.1.5 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 2.2 Merck 2.2.1 Merck Details 2.2.2 Merck Major Business 2.2.3 Merck SWOT Analysis 2.2.4 Merck Product and Services 2.2.5 Merck Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 3 Sales, Revenue and Market Share by Manufacturer 3.1 Global Neurofibromatosis Type 1 Sales and Market Share by Manufacturer (2018-2019) 3.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Manufacturer (2018-2019) 3.3 Market Concentration Rate 3.3.1 Top 3 Neurofibromatosis Type 1 Manufacturer Market Share in 2019 3.3.2 Top 6 Neurofibromatosis Type 1 Manufacturer Market Share in 2019 3.4 Market Competition Trend 4 Global Market Analysis by Regions 4.1 Global Neurofibromatosis Type 1 Sales, Revenue and Market Share by Regions 4.1.1 Global Neurofibromatosis Type 1 Sales and Market Share by Regions (2015-2020) 4.1.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Regions (2015-2020) 4.2 North America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 4.3 Europe Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 4.4 Asia-Pacific Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 4.5 South America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 4.6 Middle East and Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 5 North America by Country 5.1 North America Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country 5.1.1 North America Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020) 5.1.2 North America Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020) 5.2 United States Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 5.3 Canada Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 5.4 Mexico Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 6 Europe by Country 6.1 Europe Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country 6.1.1 Europe Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020) 6.1.2 Europe Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020) 6.2 Germany Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 6.3 UK Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 6.4 France Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 6.5 Russia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 6.6 Italy Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7 Asia-Pacific by Regions 7.1 Asia-Pacific Neurofibromatosis Type 1 Sales, Revenue and Market Share by Regions 7.1.1 Asia-Pacific Neurofibromatosis Type 1 Sales and Market Share by Regions (2015-2020) 7.1.2 Asia-Pacific Neurofibromatosis Type 1 Revenue and Market Share by Regions (2015-2020) 7.2 China Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7.3 Japan Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7.4 Korea Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7.5 India Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7.6 Southeast Asia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 7.7 Australia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 8 South America by Country 8.1 South America Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country 8.1.1 South America Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020) 8.1.2 South America Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020) 8.2 Brazil Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 8.3 Argentina Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 9 Middle East & Africa by Countries 9.1 Middle East & Africa Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country 9.1.1 Middle East & Africa Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020) 9.1.2 Middle East & Africa Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020) 9.2 Saudi Arabia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 9.3 Turkey Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 9.4 Egypt Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 9.5 South Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) 10 Market Segment by Type 10.1 Global Neurofibromatosis Type 1 Sales and Market Share by Type (2015-2020) 10.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Type (2015-2020) 10.3 Global Neurofibromatosis Type 1 Price by Type (2015-2020) 11 Global Neurofibromatosis Type 1 Market Segment by Application 11.1 Global Neurofibromatosis Type 1 Sales Market Share by Application (2015-2020) 11.2 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2015-2020) 11.3 Global Neurofibromatosis Type 1 Price by Application (2015-2020) 12 Market Forecast 12.1 Global Neurofibromatosis Type 1 Sales, Revenue and Growth Rate (2021-2025) 12.2 Neurofibromatosis Type 1 Market Forecast by Regions (2021-2025) 12.2.1 North America Neurofibromatosis Type 1 Market Forecast (2021-2025) 12.2.2 Europe Neurofibromatosis Type 1 Market Forecast (2021-2025) 12.2.3 Asia-Pacific Neurofibromatosis Type 1 Market Forecast (2021-2025) 12.2.4 South America Neurofibromatosis Type 1 Market Forecast (2021-2025) 12.2.5 Middle East & Africa Neurofibromatosis Type 1 Market Forecast (2021-2025) 12.3 Neurofibromatosis Type 1 Market Forecast by Type (2021-2025) 12.3.1 Global Neurofibromatosis Type 1 Sales Forecast by Type (2021-2025) 12.3.2 Global Neurofibromatosis Type 1 Market Share Forecast by Type (2021-2025) 12.4 Neurofibromatosis Type 1 Market Forecast by Application (2021-2025) 12.4.1 Global Neurofibromatosis Type 1 Sales Forecast by Application (2021-2025) 12.4.2 Global Neurofibromatosis Type 1 Market Share Forecast by Application (2021-2025) 13 Sales Channel, Distributors, Traders and Dealers 13.1 Sales Channel 13.1.1 Direct Marketing 13.1.2 Indirect Marketing 13.2 Distributors, Traders and Dealers 14 Research Findings and Conclusion 15 Appendix 15.1 Methodology 15.2 Data Source 15.3 Disclaimer 15.4 About US

List of Tables Table 1. Global Neurofibromatosis Type 1 Revenue (USD Million) by Type: 2015 VS 2019 VS 2025 Table 2. Breakdown of Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2 and Tier 3) Table 3. Global Neurofibromatosis Type 1 Market Size and Growth Estimation in Various Scenarios in 2020 Table 4. Global Neurofibromatosis Type 1 Revenue (USD Million) by Application: 2015 VS 2019 VS 2025 Table 5. Market Opportunities in Next Few Years Table 6. Market Risks Analysis Table 7. Market Drivers Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors Table 9. AstraZeneca Neurofibromatosis Type 1 Major Business Table 10. AstraZeneca Neurofibromatosis Type 1 Total Revenue (USD Million) (2018-2019) Table 11. AstraZeneca SWOT Analysis Table 12. AstraZeneca Neurofibromatosis Type 1 Product and Services Table 13. AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 14. Merck Basic Information, Manufacturing Base and Competitors Table 15. Merck Neurofibromatosis Type 1 Major Business Table 16. Merck Neurofibromatosis Type 1 Total Revenue (USD Million) (2018-2019) Table 17. Merck SWOT Analysis Table 18. Merck Neurofibromatosis Type 1 Product and Services Table 19. Merck Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 20. Global Neurofibromatosis Type 1 Sales by Manufacturer (2018-2019) (K Units) Table 21. Global Neurofibromatosis Type 1 Revenue by Manufacturer (2018-2019) (USD Million) Table 22. Global Neurofibromatosis Type 1 Sales by Regions (2015-2020) (K Units) Table 23. Global Neurofibromatosis Type 1 Sales Market Share by Regions (2015-2020) Table 24. Global Neurofibromatosis Type 1 Revenue by Regions (2015-2020) (USD Million) Table 25. North America Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units) Table 26. North America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020) Table 27. North America Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million) Table 28. North America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) Table 29. Europe Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units) Table 30. Europe Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020) Table 31. Europe Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million) Table 32. Asia-Pacific Neurofibromatosis Type 1 Sales by Regions (2015-2020) (K Units) Table 33. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Regions (2015-2020) Table 34. Asia-Pacific Neurofibromatosis Type 1 Revenue by Regions (2015-2020) (USD Million) Table 35. South America Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units) Table 36. South America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020) Table 37. South America Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million) Table 38. South America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) Table 39. Middle East & Africa Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units) Table 40. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020) Table 41. Middle East & Africa Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million) Table 42. Middle East & Africa Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) Table 43. Global Neurofibromatosis Type 1 Sales by Type (2015-2020) (K Units) Table 44. Global Neurofibromatosis Type 1 Sales Share by Type (2015-2020) Table 45. Global Neurofibromatosis Type 1 Revenue by Type (2015-2020) (USD Million) Table 46. Global Neurofibromatosis Type 1 Revenue Share by Type (2015-2020) Table 47. Global Neurofibromatosis Type 1 Sales by Application (2015-2020) (K Units) Table 48. Global Neurofibromatosis Type 1 Sales Share by Application (2015-2020) Table 49. Global Neurofibromatosis Type 1 Sales Forecast by Regions (2021-2025) (K Units) Table 50. Global Neurofibromatosis Type 1 Market Share Forecast by Regions (2021-2025) Table 51. Global Neurofibromatosis Type 1 Sales Forecast by Type (2021-2025) (K Units) Table 52. Global Neurofibromatosis Type 1 Market Share Forecast by Type (2021-2025) Table 53. Global Neurofibromatosis Type 1 Sales Forecast by Application (2021-2025) Table 54. Global Neurofibromatosis Type 1 Market Share Forecast by Application (2021-2025) Table 55. Direct Channel Pros & Cons Table 56. Indirect Channel Pros & Cons Table 57. Distributors/Traders/ Dealers List List of Figures Figure 1. Neurofibromatosis Type 1 Picture Figure 2. Global Sales Market Share of Neurofibromatosis Type 1 by Type in 2019 Figure 3. 10 mg Picture Figure 4. 25 mg Picture Figure 5. Neurofibromatosis Type 1 Sales Market Share by Application in 2019 Figure 6. Hospitals Picture Figure 7. Clinics Picture Figure 8. Others Picture Figure 9. Global Neurofibromatosis Type 1 Market Status and Outlook (2015-2025) (USD Million) Figure 10. United States Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 11. Canada Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 12. Mexico Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 13. Germany Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 14. France Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 15. UK Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 16. Russia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 17. Italy Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 18. China Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 19. Japan Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 20. Korea Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 21. India Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 22. Southeast Asia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 23. Australia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) (USD Million) Figure 24. Brazil Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 25. Egypt Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 26. Saudi Arabia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 27. South Africa Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 28. Turkey Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) Figure 29. Global Neurofibromatosis Type 1 Sales Market Share by Manufacturer in 2019 Figure 30. Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturer in 2019 Figure 31. Top 3 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2019 Figure 32. Top 6 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2019 Figure 33. Key Manufacturer Market Share Trend Figure 34. Global Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 35. Global Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 36. Global Neurofibromatosis Type 1 Revenue Market Share by Regions (2015-2020) Figure 37. Global Neurofibromatosis Type 1 Revenue Market Share by Regions in 2018 Figure 38. North America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) Figure 39. Europe Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) Figure 40. Asia-Pacific Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) Figure 41. South America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) Figure 42. Middle East & Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) Figure 43. North America Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 44. North America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020) Figure 45. North America Neurofibromatosis Type 1 Sales Market Share by Countries in 2018 Figure 46. North America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) (USD Million) Figure 47. North America Neurofibromatosis Type 1 Revenue Market Share by Countries in 2018 Figure 48. United States Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 49. Canada Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 50. Mexico Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 51. Europe Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 52. Europe Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) Figure 53. Europe Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019 Figure 54. Germany Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 55. UK Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 56. France Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 57. Russia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 58. Italy Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 59. Asia-Pacific Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 60. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Regions 2019 Figure 61. Asia-Pacific Neurofibromatosis Type 1 Revenue Market Share by Regions 2019 Figure 62. China Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 63. Japan Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 64. Korea Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 65. India Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 66. Southeast Asia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 67. South America Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 68. South America Neurofibromatosis Type 1 Sales Market Share by Countries in 2019 Figure 69. South America Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019 Figure 70. Brazil Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 71. Argentina Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 72. Middle East and Africa Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million) Figure 73. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Countries in 2019 Figure 74. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) Figure 75. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019 Figure 76. Saudi Arabia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 77. Egypt Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 78. Turkey Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 79. South Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units) Figure 80. Global Neurofibromatosis Type 1 Sales and Growth Rate (2021-2025) (K Units) Figure 81. Global Neurofibromatosis Type 1 Revenue and Growth Rate (2021-2025) (USD Million) Figure 82. North America Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units) Figure 83. Europe Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units) Figure 84. Asia-Pacific Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units) Figure 85. South America Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units) Figure 86. Middle East & Africa Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units) Figure 87. Sales Channel: Direct Channel vs Indirect Channel

AstraZeneca Merck